|
(P746) |
The synthetic adiponectin receptor agonist AdipoRon inhibits aortic valve fibrosis and calcification |
|
|
A. Jenke, F. Schlag, M. Yazdanyar, M. Lukic, S. Raschke, A. Lichtenberg, P. Akhyari (Düsseldorf) |
|
(P747) |
Comparison of carbohydrate antigen 125 (CA125) and N-terminal Pro-Brain natriuretic peptide (NTproBNP) for risk prediction in patients undergoing transcatheter aortic valve implantation (TAVI) |
|
|
T. Rheude, C. Pellegrini, T. Trenkwalder, J. Michel, N. P. Mayr, M. Kasel, H. Schunkert, A. Kastrati, C. Hengstenberg, O. Husser (München) |
|
(P748) |
Preliminary results of functional in-vitro myocardial performance in patients with aortic regurgitation vs. stenosis |
|
|
B. Kloth, T. Eschenhagen, H. Reichenspurner, T. Christ, E. Girdauskas (Hamburg) |
|
(P749) |
Can serum albumin predict morbidity and mortality in patients undergoing TAVR? |
|
|
A. Gassa, J.-H. Borghardt, M. Scherner, S. Ney, K. Eghbalzadeh, L.-M. Willkomm, T. K. Rudolph, S. Baldus, N. Mader, T. Wahlers, Aortenklappen-Register, Deutsches TAVI-Register (Köln) |
|
(P750) |
Titinisoformenexpression und myokardiale Fibrosierung bei unterschiedlichen hämodynamischen Formen der schweren Aortenstenose |
|
|
M. Gotzmann, S. Grabbe, D. Schöne, A. Mügge, J. Strauch, A. Tannapfel, W. A. Linke, BOREAS (Witten, Bochum) |
|
(P751) |
XAV-939 and Losartan modulate pro-fibrotic characteristics but solely XAV-939 impacts calcification of valvular interstitial cells in vitro |
|
|
C. Dittfeld, G. Reimann, J. Büttner, A. Jannasch, K. Plötze, K. Matschke, S.-M. Tugtekin (Dresden, Leipzig) |